Belay Diagnostics

Belay Diagnostics is redefining how brain and spinal cord cancers are detected. Our advanced cerebrospinal fluid (CSF) testing platforms use next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR) to identify genetic mutations, chromosomal abnormalities, and MGMT promoter methylation, providing clinicians and patients with a less invasive alternative to surgical biopsies. Our unique offerings help inform the diagnosis and management of primary CNS malignancies. We see our technological advances in CSF assays as offering clinicians alternative diagnostic tools for use in treatment decisions, while helping guide patients with a minimally invasive solution.